FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:392-394 February 8, 1996 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The conduct of medical research is in increasing jeopardy. Scarce funds for research have been strained by the emergence of new problems requiring intensive work. But a more insidious problem is compromising the ability to make progress in medical research. Secrecy about methods and results has become a common and accepted practice. The complex legal arrangements that are often required before reagents are shared impedes scientists from acquiring the materials needed to perform their work. These impediments to research appear to be arising more frequently. The following four situations, which I encountered in the past several months, illustrate many of . . . [Full Text of this Article]

References

Related Letters:

Secrecy in Research
Goodman N. W., Burris J. F., Tracy C. L., Lu B., Rosenberg S. A.
Extract | Full Text  
N Engl J Med 1996; 335:134-136, Jul 11, 1996. Correspondence

This article has been cited by other articles:

• Lexchin, J. R (2005). Implications of Pharmaceutical Industry Funding on Clinical Research. The Annals of Pharmacotherapy 39: 194-197 [Abstract] [Full Text]  
• DuVal, G (2004). Institutional ethics review of clinical study agreements. J. Med. Ethics 30: 30-34 [Abstract] [Full Text]  
• Schulman, K. A., Seils, D. M., Timbie, J. W., Sugarman, J., Dame, L. A., Weinfurt, K. P., Mark, D. B., Califf, R. M. (2002). A National Survey of Provisions in Clinical-Trial Agreements between Medical Schools and Industry Sponsors. NEJM 347: 1335-1341 [Abstract] [Full Text]  
• Barnes, M., Florencio, P. S. (2002). Financial Conflicts of Interest in Human Subjects Research: The Problem of Institutional Conflicts. J Law Med Ethics 30: 390-402  
• Schechter, A. N. (1998). The Crisis in Clinical Research: Endangering the Half-Century National Institutes of Health Consensus. JAMA 280: 1440-1442 [Full Text]  
• Kodish, E. (1997). Commentary: Risks and Benefits, Testing and Screening, Cancer, Genes and Dollars. J Law Med Ethics 25: 252-255  
• Goodman, N. W., Burris, J. F., Tracy, C. L., Lu, B., Rosenberg, S. A. (1996). Secrecy in Research. NEJM 335: 134-136 [Full Text]  
• Shaughnessy, A. F, Slawson, D. C (1996). Pharmaceutical representatives. BMJ 312: 1494-1494 [Full Text]  
• Blumenthal, D., Causino, N., Campbell, E., Louis, K. S. (1996). Relationships between Academic Institutions and Industry in the Life Sciences -- An Industry Survey. NEJM 334: 368-374 [Abstract] [Full Text]